Probiotics for Diarrhea: Evidence-Based Strains and What the Research Actually Shows
A science-first look at which probiotic strains have clinical backing for antibiotic-associated, infectious, and IBS-related diarrhea—and what the evidence honestly says
Few digestive symptoms disrupt daily life as immediately as diarrhea—and few supplement claims are as confidently overstated as the ones made about probiotics and diarrhea relief. The honest reality is more nuanced: the research is real, the benefits are strain-specific, and the evidence is strongest for certain types of diarrhea over others.
This article unpacks what peer-reviewed science actually shows about probiotic strains and diarrhea—covering antibiotic-associated diarrhea, diarrhea-predominant IBS, and acute infectious diarrhea. We'll focus only on strains present in MicroBiome Restore, examining their mechanisms of action and the clinical trials that support (or complicate) their use. Where the evidence is strong, we'll say so. Where it's preliminary or conflicting, we'll say that too.
If you're also dealing with broader gut imbalance that underlies chronic loose stools, our article on probiotics for gut dysbiosis provides relevant context for understanding why diarrhea often points to a microbiome-level problem rather than just a transient symptom.
Key Takeaways
- Probiotic effects on diarrhea are strain-specific and context-dependent. The strongest clinical evidence is for antibiotic-associated diarrhea (AAD), where specific strains demonstrably reduce risk. Evidence for acute infectious diarrhea is more nuanced, and for IBS-related diarrhea, multi-strain formulas show genuine promise.
- Lactobacillus rhamnosus is among the most evidence-backed strains for AAD. A meta-analysis of 12 RCTs found L. rhamnosus GG reduced AAD risk by approximately 50% (from 22.4% to 12.3%) in patients taking antibiotics for any reason.[1]
- Multi-strain formulas outperform single strains for diarrhea-predominant IBS in several trials, with combinations spanning Lactobacillus and Bifidobacterium genera showing additive benefits on stool consistency, abdominal pain, and bowel frequency.[2]
- Bacillus coagulans produced statistically significant improvements in diarrhea, bloating, and abdominal pain in IBS patients in a double-blind RCT, and its spore-forming nature means it is more stable in supplement form than vegetative Lactobacillus strains.[3]
- Bifidobacterium longum has demonstrated diarrhea reduction in rotavirus infections and significant IBS-D symptom relief in multiple clinical trials, including a large post-market follow-up study.[4]
- How probiotics work matters: Probiotic strains reduce diarrhea through at least four distinct mechanisms—competitive exclusion of pathogens, short-chain fatty acid (SCFA) production, intestinal barrier reinforcement, and immune modulation—which is why strain diversity and prebiotic support both matter.[5]
- Filler-free formulas matter for gut health. Many commercial probiotic capsules contain microcrystalline cellulose, magnesium stearate, and other additives that can undermine the very gut lining that probiotic bacteria work to restore. Starting with a clean-label formula removes this contradiction.
How Probiotics Work Against Diarrhea
Before examining specific strains, it's worth understanding the mechanisms through which probiotics exert their effects on diarrheal conditions. The gut is not simply a tube—it's a dynamic ecosystem where microbial composition, intestinal barrier integrity, immune signaling, and metabolite production all interact. Diarrhea, in most of its forms, involves disruption to one or more of these systems.
Competitive Exclusion
Probiotic bacteria compete with pathogens for adhesion sites on intestinal epithelial cells and the overlying mucus layer. By physically occupying these sites and producing antimicrobial compounds (including lactic acid, acetic acid, and bacteriocins), beneficial bacteria can directly prevent pathogenic colonization.[6] This is especially relevant for antibiotic-associated diarrhea, where the disruption of normal flora creates ecological space for opportunistic pathogens to thrive.
Short-Chain Fatty Acid Production and Water Absorption
One of the most clinically significant mechanisms involves SCFA production. When probiotic bacteria ferment dietary fiber, they produce butyrate, acetate, and propionate—metabolites that serve as the primary energy source for colonocytes, support tight junction protein expression, and are directly involved in regulating water and sodium absorption in the colon.[5] Reduced SCFA production is a consistent feature of antibiotic-disrupted gut microbiomes, and its restoration is a key mechanism by which probiotics counter diarrhea.
Intestinal Barrier Reinforcement
Diarrhea is frequently associated with increased intestinal permeability—a loosening of the tight junctions between epithelial cells that allows luminal contents to pass into the bloodstream and disrupts normal fluid regulation. Multiple Lactobacillus and Bifidobacterium species have demonstrated the capacity to upregulate tight junction proteins such as ZO-1, occludin, and claudin, restoring barrier integrity.[7] This is particularly relevant for post-infectious diarrhea and the loose stools associated with IBS.
Immune Modulation
Probiotic strains interact directly with mucosal immune cells, influencing the balance of pro-inflammatory and anti-inflammatory cytokines. By promoting IL-10 production and suppressing TNF-α and IL-6, certain strains can dampen the inflammatory cascade that amplifies intestinal fluid secretion and accelerates transit—both hallmarks of diarrhea.[5] This immune modulation also explains why some probiotic strains show benefit across both infectious and non-infectious diarrheal conditions.
The Dysbiosis Connection
Diarrhea is rarely an isolated event—it's frequently a downstream symptom of gut dysbiosis: an imbalance in the composition, diversity, or metabolic function of the gut microbiome. Antibiotics are the most common acute trigger, but chronic dysbiosis driven by poor diet, stress, and prior antibiotic exposure creates a vulnerability to persistent loose stools. Probiotic supplementation works most meaningfully when it's part of a strategy to restore—not just temporarily boost—microbial diversity and function.
Probiotics for Antibiotic-Associated Diarrhea
Antibiotic-associated diarrhea (AAD) is the best-studied indication for probiotic use, with the most consistent clinical evidence across multiple meta-analyses. It affects an estimated 5–35% of people who take antibiotics, depending on the antibiotic class, duration of treatment, and individual microbiome resilience.[8] The mechanism is straightforward: broad-spectrum antibiotics indiscriminately reduce commensal bacteria, disrupt SCFA metabolism, allow osmotic accumulation of carbohydrates in the colon, and create conditions favorable to pathogen overgrowth.
Why Probiotic Timing Matters for AAD
One consistently supported finding is that starting probiotics early—ideally within 48 hours of beginning antibiotic therapy—significantly improves outcomes. A meta-analysis examining outpatient antibiotic use found that probiotic supplementation reduced AAD incidence from 17.7% in control groups to 8.0% in probiotic groups (relative risk 0.49, 95% CI 0.36–0.66).[8] Waiting until diarrhea has already developed is less effective; the protective window is during concurrent or near-concurrent use.
An Honest Note on the Research Landscape
The evidence for probiotics and diarrhea varies significantly by indication. For antibiotic-associated diarrhea, the evidence is robust and consistent across multiple meta-analyses. For IBS-related diarrhea, multi-strain formulas show genuine promise, particularly in recent, better-designed trials. For acute infectious diarrhea—the kind caused by viruses or bacteria—a 2020 Cochrane Review that analyzed 82 RCTs (12,127 participants) concluded that high-quality evidence does not confirm a significant reduction in diarrhea duration in high-income country settings.[9] Earlier, smaller trials showing positive effects likely suffered from publication bias. This doesn't mean probiotics provide no benefit for acute infectious diarrhea—but it means the evidence doesn't support strong claims, and we won't make them here.
Spore-Forming Probiotics and Antibiotic Resistance
A practical consideration specific to AAD is survivability. Most vegetative Lactobacillus strains can be partially inactivated by antibiotic treatment—the same antibiotics that are causing the diarrhea. Spore-forming strains such as Bacillus coagulans are uniquely suited to this context because their spore coat is largely resistant to antibiotic damage, allowing them to remain viable and active in the gut during antibiotic treatment. This is one reason multi-strain formulas including both Lactobacillus/Bifidobacterium strains and spore-forming Bacillus strains may offer more complete coverage during antibiotic courses than Lactobacillus-only formulas.
Supporting Your Gut Through Antibiotic Treatment
MicroBiome Restore contains Lactobacillus rhamnosus alongside five Bacillus strains—including the spore-forming B. coagulans—and five Bifidobacterium species, giving you coverage across vegetative and spore-forming strains during antibiotic courses.
Probiotics for IBS-Related Diarrhea
Diarrhea-predominant IBS (IBS-D) presents a distinct clinical challenge from acute or antibiotic-induced diarrhea. It is chronic, often unpredictable, and involves a complex interplay of gut dysmotility, visceral hypersensitivity, altered gut-brain axis signaling, and—increasingly recognized as central—gut microbiome dysbiosis. This article won't go deep on IBS pathophysiology since we have a dedicated article on probiotics for IBS, but we'll address the diarrhea-specific evidence.
Multi-Strain Formulas Show the Strongest IBS-D Evidence
A 2022 randomized, double-blind, placebo-controlled trial evaluated a multi-strain probiotic containing Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactiplantibacillus plantarum, Lacticaseibacillus rhamnosus, and Ligilactobacillus salivarius in children with antibiotic-associated diarrhea at a combined dose of 10 billion CFU. The probiotic group experienced significantly fewer cases of AAD compared to placebo.[2]
For IBS-D specifically, a post-hoc microbiome analysis from an RCT using a multi-strain formula containing L. acidophilus, L. plantarum, L. rhamnosus, B. breve, B. lactis, B. longum, and Streptococcus thermophilus found that patients who responded to probiotic therapy showed significantly different microbiome shifts compared to non-responders.[10] This highlights an important point: probiotic efficacy in IBS-D likely depends on an individual's baseline microbiome composition—which may partly explain trial heterogeneity.
Bifidobacterium longum and IBS-D: A Closer Look
Among Bifidobacterium strains, B. longum has a particularly well-developed clinical evidence base for IBS-D. A large observational study of 278 IBS patients found that 30 days of once-daily B. longum 35624 supplementation produced significant improvements in IBS severity scores, with diarrhea and bloating showing statistically significant reductions as early as 2 weeks into treatment. Over 60% of participants achieved clinically meaningful reductions in symptom severity.[4]
A separate randomized, double-blind, placebo-controlled trial specifically in IBS-D patients using B. longum CECT 7347 found a mean decrease in IBS Severity Scoring System (IBS-SSS) scores from baseline of approximately 174 points—compared to just 60 points in the placebo group (p < 0.0001).[11] Secondary outcomes including stool consistency and abdominal pain scores also improved significantly.
Prebiotic Support for IBS-D: A Key Often Overlooked
In IBS-D specifically, the fiber source powering your probiotic strains matters. Soluble, fermentable fibers like acacia and inulin (from Jerusalem artichoke) feed Lactobacillus and Bifidobacterium selectively—but at the right dose, these same fibers are generally well-tolerated even by people with sensitive digestive systems. MicroBiome Restore includes acacia fiber, Jerusalem artichoke, maitake mushroom, bladderwrack, Norwegian kelp, oarweed, and fig fruit as prebiotic sources—chosen for both efficacy and digestive tolerability.
Probiotics for Acute Infectious Diarrhea
As noted above, the evidence for probiotics treating acute infectious diarrhea has become more nuanced since the 2020 updated Cochrane Review. What earlier smaller trials suggested as significant duration reduction was called into question when larger, better-designed trials from North America did not replicate those effects—likely due to publication bias in the earlier literature.[9]
That said, the biological rationale remains sound: certain probiotic strains produce direct anti-pathogen effects, and multiple mechanisms (competitive exclusion, barrier reinforcement, immune modulation) are plausibly relevant against viral and bacterial enteropathogens. Research at the cellular level continues to show that probiotic strains can inhibit pathogen adhesion and reduce pro-inflammatory cytokine expression during infection.[6]
Where there is more consistent evidence for acute infectious contexts is in specific populations—particularly infants and young children in certain geographic and clinical settings. A combination of B. longum and L. acidophilus significantly shortened diarrhea duration by 1.2 days (p = 0.001) in infants hospitalized with rotavirus infection in a double-blind RCT.[12] A separate trial administering six probiotic strains including B. longum, B. lactis, L. acidophilus, L. rhamnosus, L. plantarum, and Pediococcus pentosaceus to pediatric patients with viral gastroenteritis found that these probiotics significantly shortened the duration of diarrhea compared to placebo (6.1 ± 0.5 days vs 7.2 ± 1.9 days; p = 0.030).[13]
For adults dealing with acute infectious diarrhea, probiotics are a reasonable adjunct—particularly those who are also completing antibiotic treatment (which converts the picture to AAD) or those looking to restore gut function in the recovery period following illness. Our dedicated article on probiotics after antibiotics covers post-infection recovery in more detail.
Key Probiotic Strains for Diarrhea: What's in MicroBiome Restore and Why
The following is an evidence-focused review of the specific strains present in MicroBiome Restore that have the most clinically relevant evidence for diarrheal conditions. Not every strain in a 26-strain formula will have dedicated diarrhea trials—and that's fine. What matters is whether the formula's composition reflects the genera and species that research has identified as meaningfully supportive.
Lactobacillus rhamnosus: The Best-Studied Strain for AAD
No probiotic strain has more direct clinical trial evidence for antibiotic-associated diarrhea prevention than L. rhamnosus. A meta-analysis of 12 RCTs covering 1,499 participants found that treatment with L. rhamnosus GG reduced AAD risk overall from 22.4% to 12.3% (RR: 0.49, 95% CI: 0.29–0.83).[1] In children specifically, where five studies provided moderate-quality evidence, the reduction was even more pronounced (from 23% to 9.6%).[1]
L. rhamnosus also supports the intestinal barrier: it has been shown to alleviate barrier dysfunction by increasing expression of zonula occludens-1 (ZO-1) and myosin light-chain kinase—tight junction proteins that regulate paracellular permeability.[7] Read more about the broader evidence behind Lactobacillus rhamnosus benefits.
Bacillus coagulans: Spore-Forming Stability for IBS-D and AAD
Bacillus coagulans occupies a unique position in probiotic formulas for diarrhea because it is spore-forming. Its endospore structure allows it to survive antibiotic exposure, stomach acid, and heat that would inactivate vegetative Lactobacillus strains—making it particularly relevant when diarrhea is antibiotic-related or when digestive conditions are harsh. A double-blind, randomized, placebo-controlled trial specifically in diarrhea-predominant IBS patients found that B. coagulans MTCC 5856 produced statistically significant improvements in diarrhea (p = 0.0026), stool frequency (p = 0.0031), and abdominal pain (p = 0.0001) compared to placebo over 90 days.[3]
A separate synbiotic trial found that B. coagulans significantly reduced diarrhea frequency in IBS patients and maintained this benefit through a nine-month follow-up—a durability of effect that is unusual in probiotic research.[14] For more on this strain, see our detailed review of Bacillus coagulans benefits.
Bifidobacterium longum: Durable IBS-D Relief
As covered above, B. longum has demonstrated some of the most consistent clinical results specifically for diarrhea-predominant IBS. Its mechanisms include modulation of gut motility through serotonin-pathway interactions, reduction of visceral hypersensitivity, and production of short-chain fatty acids that regulate colon water absorption. In a large observational trial, diarrhea scores fell significantly from baseline after just two weeks of once-daily supplementation—with over 60% of patients achieving clinically meaningful responses by the end of eight weeks.[4] Understanding how Bifidobacterium strains support gut health broadly provides additional context for why this genus appears in virtually every well-designed multi-strain formula for gut complaints.
Lactobacillus acidophilus: Multi-Context Antidiarrheal Evidence
L. acidophilus has been studied across multiple diarrheal contexts. In combination with B. longum, it significantly shortened diarrhea duration in rotavirus-infected infants (p = 0.001) compared to placebo.[12] At the cellular level, L. acidophilus and Streptococcus thermophilus have been shown to limit the adhesion and invasion of enteroinvasive E. coli in intestinal epithelial cell models.[15] A review of the broader evidence for Lactobacillus acidophilus benefits covers this strain's clinical range in more detail.
Lactobacillus plantarum: Barrier Protection and IBS-D Symptom Relief
L. plantarum is one of the most metabolically versatile probiotic strains in the Lactobacillus genus. Its relevance to diarrhea rests primarily on its barrier-protective effects: multiple studies have demonstrated its capacity to upregulate tight junction proteins and reduce intestinal permeability—the physiological underpinning of loose, frequent stools.[7]
Clinically, a randomized, double-blind, placebo-controlled, multi-center dose-ranging study in adults with IBS-D found that L. plantarum Lpla33 produced significant dose-dependent reductions in stool consistency, abdominal pain, and IBS symptom severity scores. The higher-dose group achieved a clinically relevant >30% reduction in abdominal pain severity and a mean increase in IBS-related quality of life above the threshold for clinical meaningfulness.[16] Explore the full range of Lactobacillus plantarum health benefits in our dedicated guide.
Bifidobacterium breve, Bifidobacterium bifidum, and Bifidobacterium lactis
These three Bifidobacterium species round out the formula's Bifidobacterium coverage and bring distinct immunomodulatory mechanisms to the diarrhea picture. B. breve and B. bifidum have demonstrated significant effects on pro-inflammatory cytokines (including TNF-α and IL-6) during pathogenic challenge, with each strain showing differential cytokine regulation depending on the immune context.[17] Clinical work using B. breve as an adjuvant treatment for acute diarrhea in children found beneficial effects on diarrhea duration and immunological markers. B. lactis appeared in one of the key multi-strain IBS-D responder analyses, where its abundance increased significantly post-treatment in patients who responded to probiotic therapy—further supporting its role in microbiome modulation relevant to loose stools.[10]
Streptococcus thermophilus: Barrier Defense and Pathogen Inhibition
Streptococcus thermophilus is often included in multi-strain probiotic formulas as a synergistic partner to Lactobacillus strains. It produces lactic acid that lowers luminal pH, inhibiting the growth of acid-sensitive pathogens, and has been shown to limit E. coli adhesion to intestinal epithelial cells. Research on Streptococcus thermophilus supports its role in formulas targeting infectious and post-antibiotic dysbiosis. It has also appeared in maternal probiotic research as one of three genera specifically cited for infant gut health benefits.
| Strain | Primary Diarrhea-Relevant Evidence | Mechanism |
|---|---|---|
| L. rhamnosus | Reduced AAD risk by ~50% in meta-analysis of 12 RCTs[1] | Competitive exclusion; barrier reinforcement (ZO-1) |
| B. coagulans | Significant IBS-D diarrhea reduction in 90-day RCT[3] | Spore-form stability; SCFA production; immune modulation |
| B. longum | >60% of IBS-D patients achieved clinically meaningful response[4] | Motility modulation; SCFA; visceral hypersensitivity reduction |
| L. acidophilus | Shortened rotavirus diarrhea in RCT (p = 0.001)[12] | Pathogen adhesion inhibition; tight junction support |
| L. plantarum | Significant IBS-D stool and pain improvement in dose-ranging RCT[16] | Barrier integrity; anti-inflammatory cytokine modulation |
| B. breve / B. bifidum / B. lactis | Immunomodulatory cytokine effects; IBS-D responder association[17] | TNF-α, IL-6 modulation; microbiome diversity support |
| S. thermophilus | Pathogen adhesion inhibition; AAD synergy in combined formulas[15] | Luminal pH reduction; competitive exclusion |
Timing, Dosage, and What to Look For in a Probiotic for Diarrhea
When to Start—and How Long to Continue
For antibiotic-associated diarrhea prevention, the evidence strongly favors starting probiotic supplementation at the same time as—or within 48 hours of beginning—antibiotic treatment.[8] Waiting until diarrhea develops is less protective. Continue supplementation for the full duration of the antibiotic course and ideally for 1–2 weeks beyond its completion to support microbiome recovery. Our guide on probiotics after antibiotics covers the recovery window in detail.
For IBS-D, clinical trials demonstrating meaningful results have typically used supplementation periods of 4–12 weeks. Diarrhea-related improvements in the B. longum studies began appearing within 2 weeks, suggesting that for stool-consistency outcomes, early response is possible—though sustained use is associated with more durable benefits. For general guidance on when to take probiotics, our dedicated article covers both timing within the day and timing relative to meals.
CFU Count: Is More Always Better?
The effective CFU doses in most well-designed diarrhea trials range from 1 billion to 10 billion CFU per strain, or comparable total CFU in multi-strain formulas. A meta-analysis evaluating AAD prevention in outpatients found no significant difference in benefit between studies using higher versus lower CFU doses, though higher doses showed a trend toward more consistent results.[8] What matters more than total CFU is strain diversity and the quality of the surrounding formula—including prebiotic substrates that help strains establish and proliferate.
MicroBiome Restore delivers 15 billion CFU across 26 strains—a meaningful and clinically relevant dose that aligns with the therapeutic ranges used in published trials. This isn't an industry-maximum "50 billion CFU" formula chasing a marketing number; it's a thoughtfully dosed multi-strain synbiotic built around clinical evidence.
Why Filler-Free Formulation Matters for Diarrhea Specifically
People seeking probiotic support for diarrhea often have a gut lining that is already compromised—barrier function is impaired, inflammatory tone is elevated, and the mucosal environment is disrupted. Introducing probiotic bacteria alongside additives that themselves disrupt the gut lining compounds the problem.
Microcrystalline cellulose, magnesium stearate, and titanium dioxide are standard fillers in mass-market probiotics with emerging evidence of gut mucosal and microbiome disruption. For someone managing diarrhea—where the mucosal barrier is the central therapeutic target—these are not incidental concerns. They're a reason to read labels carefully, as our guide to identifying hidden fillers in probiotic labels explains.
Checklist: Choosing a Probiotic for Diarrhea
Look for: Multi-strain formula spanning Lactobacillus, Bifidobacterium, and ideally spore-forming strains (Bacillus); strains with published clinical evidence for AAD or IBS-D specifically; included prebiotic fiber; filler-free formulation; delayed-release or pullulan capsule technology for improved GI survivability.
Avoid: Single-strain formulas without AAD or IBS-D evidence; formulas containing microcrystalline cellulose, magnesium stearate, or titanium dioxide; synthetic flow agents that compromise gut barrier function; proprietary blends that obscure per-strain CFU amounts; products that begin antibiotic course use after diarrhea has already developed.
Frequently Asked Questions
Should I take a probiotic while I have diarrhea?
It depends on the cause. For antibiotic-associated diarrhea, starting probiotics as early as possible—ideally at the same time as the antibiotic, not after diarrhea develops—has the strongest evidence.[8] For IBS-related diarrhea, consistent daily supplementation is the evidence-based approach rather than episodic use. For acute infectious diarrhea, the evidence is less conclusive in adults in high-income settings—but probiotic use is generally safe and may support recovery. If fever is present, stool contains blood, or diarrhea is severe and prolonged, consult a healthcare provider before self-treating with any supplement.
Can probiotics make diarrhea worse?
For most healthy adults, probiotics are safe and well-tolerated. Some people experience mild transient changes in stool consistency or gas when beginning a new probiotic—this typically resolves within a few days as the gut microbiome adjusts. In the AAD prevention meta-analysis, adverse event rates between probiotic and control groups were not significantly different.[8] Immunocompromised individuals or those with serious underlying conditions should consult a physician before beginning supplementation, as rare cases of bacteremia have been reported in these populations.
What's the best probiotic for antibiotic-induced diarrhea?
Based on the clinical literature, a formula that includes Lactobacillus rhamnosus and spore-forming Bacillus strains (such as B. coagulans) is best suited for antibiotic-associated diarrhea. L. rhamnosus has the most direct AAD-specific meta-analysis evidence,[1] and spore-forming strains remain active during antibiotic treatment when vegetative strains may be partially suppressed. Bifidobacterium species complement this coverage by supporting SCFA production and mucosal immunity. A multi-strain formula covering all three genera is the evidence-aligned approach.
How long does it take for probiotics to work for diarrhea?
For antibiotic-associated diarrhea prevention, probiotics must be started before or at the onset of antibiotic treatment—they work prophylactically, not reactively. For IBS-D, clinical trials show measurable stool consistency improvement as early as 2 weeks in the case of B. longum,[4] though the majority of trials assess outcomes over 8–12 weeks for sustained benefit. Expect a minimum of 2–4 weeks before evaluating response for chronic diarrheal conditions.
Are probiotics safe long-term for diarrhea management?
Yes, for the vast majority of healthy individuals. Clinical trials for IBS-D have extended to 90 days or longer with no serious adverse events reported for the strains studied here.[3] One synbiotic trial found that the benefit from Bacillus coagulans on diarrhea frequency persisted at nine-month follow-up—the longest post-treatment assessment in this literature.[14] Long-term probiotic use appears safe and may offer compounding benefits as the gut microbiome stabilizes toward greater diversity and resilience.
Do prebiotics help with diarrhea too?
Yes, but selectively. Prebiotics feed beneficial bacteria and support SCFA production—both directly relevant to diarrhea management. However, rapidly fermentable fibers taken in excess can worsen loose stools in people with IBS, particularly those with sensitivity to fermentable oligosaccharides. The prebiotic sources in MicroBiome Restore—acacia fiber, Jerusalem artichoke inulin, maitake mushroom beta-glucans, bladderwrack, Norwegian kelp, oarweed, and fig fruit—include a combination of soluble and prebiotic polysaccharides that tend to be better tolerated in sensitive digestive systems than high-dose inulin alone. Research on acacia as a prebiotic for sensitive guts specifically found favorable tolerability compared to other fermentable fibers.
The Bottom Line on Probiotics for Diarrhea
The evidence supporting probiotics for diarrhea is real—but it's specific. The strongest case is for antibiotic-associated diarrhea prevention, where meta-analyses consistently show roughly a 50% risk reduction with strains like L. rhamnosus. For IBS-D, multi-strain formulas including Bifidobacterium longum, L. rhamnosus, L. plantarum, and B. coagulans have shown clinically meaningful improvements in stool consistency, abdominal pain, and quality of life in well-designed trials. For acute infectious diarrhea, the picture is more complicated—large, high-quality trials have not confirmed the duration-shortening effects shown in older, smaller studies.
What's clear across all contexts is that strain diversity matters, prebiotic support matters, and the absence of gut-disrupting fillers matters—particularly when the therapeutic target is the intestinal barrier and mucosal immune environment. A formula that combines clinically studied strains with organic prebiotic substrates in a filler-free capsule isn't just better marketing. It's a more complete approach to the underlying biology.
If you're interested in understanding how MicroBiome Restore's formula was built around these principles, our complete guide to MicroBiome Restore covers the full ingredient rationale, strain selection, and clean-label philosophy that distinguishes the formula from commodity probiotics.
26 Evidence-Backed Strains. 7 Organic Prebiotics. Zero Fillers.
MicroBiome Restore delivers Lactobacillus rhamnosus, Bacillus coagulans, Bifidobacterium longum, L. plantarum, L. acidophilus, and 21 additional strains in a synbiotic formula built around clinical evidence—not marketing. Pullulan capsules. No MCC, no magnesium stearate, no titanium dioxide.
References
- Szajewska, H., & Kołodziej, M. (2015). Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Alimentary Pharmacology & Therapeutics, 42(10), 1149–1157. https://doi.org/10.1111/apt.13404
- Łukasik, J., Dierikx, T., Besseling-van der Vaart, I., de Meij, T., & Szajewska, H. (2022). Multispecies probiotic for the prevention of antibiotic-associated diarrhea in children: A randomized clinical trial. JAMA Pediatrics, 176(9), e221424. https://doi.org/10.1001/jamapediatrics.2022.1424
- Majeed, M., Nagabhushanam, K., Natarajan, S., Sivakumar, A., Ali, F., Pande, A., Majeed, S., & Karri, S. K. (2016). Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutrition Journal, 15(1), 21. https://doi.org/10.1186/s12937-016-0140-6
- Elsenbruch, S., Langhorst, J., Popkirova, K., Wagner, J., Siepmann, M., Enck, P., & Benson, S. (2022). Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World Journal of Gastroenterology, 28(8), 833–845. https://doi.org/10.3748/wjg.v28.i8.833
- Verce, M., De Vuyst, L., & Weckx, S. (2020). Molecular mechanisms of probiotic prevention of antibiotic-associated diarrhea. Current Opinion in Biotechnology, 61, 59–66. https://doi.org/10.1016/j.copbio.2019.10.007
- Iancu, M. A., Profir, M., Roşu, O. A., Ionescu, R. F., Cretoiu, S. M., & Gaspar, B. S. (2023). Revisiting the intestinal microbiome and its role in diarrhea and constipation. Microorganisms, 11(9), 2177. https://doi.org/10.3390/microorganisms11092177
- Czerucka, D., Piche, T., & Rampal, P. (2007). Review article: yeast as probiotics — Saccharomyces boulardii. Alimentary Pharmacology & Therapeutics, 26(6), 767–778; see also Miyauchi, E., Morita, H., & Tanabe, S. (2009). Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo. Journal of Dairy Science, 92(6), 2400–2408. https://doi.org/10.3168/jds.2008-1698
- Blaabjerg, S., Artzi, D. M., & Aabenhus, R. (2017). Probiotics for the prevention of antibiotic-associated diarrhea in outpatients—a systematic review and meta-analysis. Antibiotics, 6(4), 21. https://doi.org/10.3390/antibiotics6040021
- Collinson, S., Deans, A., Padua-Zamora, A., Gregorio, G. V., Li, C., Dans, L. F., & Allen, S. J. (2020). Probiotics for treating acute infectious diarrhoea. Cochrane Database of Systematic Reviews, 12(12), CD003048. https://doi.org/10.1002/14651858.CD003048.pub4
- Ki Cha, B., Mun Jung, S., Hwan Choi, C., Song, I. D., Woong Lee, H., Joon Kim, H., Hyuk, J., Kyung Chang, S., Kim, K., Chung, W. S., & Seo, J. G. (2012). The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Gastroenterology, 46(3), 220–227. https://doi.org/10.1097/MCG.0b013e31823712b1
- Kuttapuram, J., Pavan, R., Gupte, U., Doshi, J., Doshi, S., Sahoo, T., & Anand, R. K. (2024). A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14802
- Park, M. S., Kwon, B., Ku, S., & Ji, G. E. (2017). The efficacy of Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 probiotic treatment in infants with rotavirus infection. Nutrients, 9(8), 887. https://doi.org/10.3390/nu9080887
- Lee, D. K., Kang, J. Y., Shin, H. S., Park, I. H., Ha, N. J., & Kim, D. H. (2015). Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients. Clinics and Research in Hepatology and Gastroenterology, 39(2), 237–244. https://doi.org/10.1016/j.clinre.2014.09.001
- Rogha, M., Esfahani, M. Z., & Zargarzadeh, A. H. (2014). The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterology and Hepatology from Bed to Bench, 7(3), 156–163. https://pmc.ncbi.nlm.nih.gov/articles/PMC4129566/
- Iancu, M. A., Profir, M., Roşu, O. A., Ionescu, R. F., Cretoiu, S. M., & Gaspar, B. S. (2023). Revisiting the intestinal microbiome and its role in diarrhea and constipation. Microorganisms, 11(9), 2177. https://doi.org/10.3390/microorganisms11092177
- Mujagic, Z., de Vos, P., Boekschoten, M. V., Govers, C., Pieters, H. H., de Wit, N. J., Bron, P. A., Masclee, A. A., & Troost, F. J. (2023). Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome. Journal of Neurogastroenterology and Motility, 29(3), 336–348. https://doi.org/10.5056/jnm22061
- Park, J. H., Lee, J. H., & Cho, C. H. (2022). Immunomodulatory effects of Bifidobacterium spp. and use of Bifidobacterium breve and Bifidobacterium longum on acute diarrhea in children. Nutrients, 14(19), 3958. https://doi.org/10.3390/nu14193958
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!